Fidelity Select Biotechnology Portfolio (FBIOX) a Zacks Ranked #2 (Buy) was incepted in December 1985 and managed by the Fidelity Group, the objective of this fund is to seek capital appreciation. FBIOX normally invests at least 80% of assets in common stocks of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes and companies that benefit significantly from scientific and technological advances in biotechnology.
This Sector-Health product, as of the last filing, allocates their fund in one major group; Small Growth. Further, as of the last filing, Alexion Pharmaceuticals (NASDAQ:ALXN), Inc., Regeneron Pharmaceuticals, Inc. and Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated were the top holdings for FBIOX.
Fidelity Select Biotechnology Portfolio, managed by Fidelity, carries an expense ratio of 0.72%. Moreover, FBIOX requires a minimal initial investment of $2,500.
FBIOX has a history of positive total returns for over 10 years. Specifically, the fund’s returns over the 3, 5 year benchmarks; 3 year 14.52% and 5 year 21.18%. To see how this fund performed compared in its category, please click here.
FBIOX’s performance, as of the last filing, when compared to funds in its category was in the top 87% in 1 year, top 53% over the past 3 years, and in the 2% over the past 5 years.
Zacks Premium
To see the Zacks Mutual Fund Rank for the funds you’re interested in —plus, gain access to the Zacks Rank for your stocks and ETFs; Premium Screens; Equity Research Reports; Focus List portfolio of 50-longer-term stocks and more— start your 30-day free trial to Zacks Premium.
View All Zacks #1 Ranked Mutual Funds
Get Your Free (FBIOX): Fund Analysis Report
Original post
Zacks Investment Research